IL37 and ulcerative colitis: Furthermore, the IL-23 inhibitor group showed significantly reduced risks of adverse events leading to treatment discontinuation (RR = 0.29, 95% CI: 0.19–0.45, p < 0.001) and worsening of ulcerative colitis (RR = 0.28, 95% CI: 0.20–0.38, p < 0.001).